Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Wednesday, September 23, 2026

Snapshot: Sep 23, 2026 · 5:00 PM 100 stocks analyzed

Strong Up Day

Wed, Sep 23, 2026 Divergent High

Nasdaq surges 5.3% in a divergent rally led by mega-cap tech while healthcare and small caps lag, with extreme single-stock dispersion masking an uneven market underneath.

55% Nasdaq 100 jumped 5.27% as large-cap tech and mega-cap growth stocks carried the day, with the S&P 500 gaining 2.04% despite the Russell 2000 and mid-caps turning negative—a classic tech-led divergence that left value and small-cap investors behind. VIX barely budged down 1.68%, signaling conviction was measured.
30% Extreme dispersion ruled the tape: 50 gainers averaged +26.6% with max moves like GCTK +92.9% (LT-100 clinical update) and GCDT +47.3% (reverse split), while 50 losers averaged -23.7% with ARCI cratering -94.5% and JAGX -77.5%, creating a wild edge-to-edge landscape where stock-picking trumped index-following.
15% Healthcare dominated the losers list with 37% of declines—including ADGM -51.8% on strategic review, IMCC -30.4% on dilutive offering, and ALKT -19.3% after board rejected sale—while the same sector grabbed 29% of gainers, highlighting internal sector bifurcation and rotation between growth and value within healthcare itself.

Healthcare drove 37% of losers 5 names returned after long absences KLXER · 4-day losers streak KOSS — first appearance CGEM — first appearance

Market Regime

Wed, Sep 23, 2026 Neutral conf: medium macro · prototype

+20

Tailwind −100 … +100 · + tailwind / − headwind

VIX15.2 p16 Drawdown-1.2% Held1d · nascent SinceSep 23

Top drivers: VIX percentile ▲ Small-cap leadership ▼ S&P drawdown (60d) ▲

processId: history-market-regime

Market Indexes

Wed, Sep 23, 2026 13

S&P 500

7,706.03

+154.22

+2.04%

Dow Jones

51,511.59

+49.69

+0.10%

NASDAQ Composite

26,936.04

+957.61

+3.69%

NASDAQ 100

30,470.29

+1,525.23

+5.27%

DJ US Total Market

75,987.94

+1,409.52

+1.89%

Russell 1000

4,189.17

+78.69

+1.91%

S&P MidCap 400

3,652.74

+12.17

+0.33%

Russell 2000

2,838.66

−20.15

-0.70%

Russell 2500

1,219.36

−15.18

-1.23%

Russell 3000

4,363.37

+77.48

+1.81%

Nasdaq Financial-100

7,437.41

−66.77

-0.89%

NIFTY 50

23,446.80

+176.20

+0.76%

VIX

15.18

−0.26

-1.68%

Biggest Gainers

Wed, Sep 23, 2026 50

GCTK

GlucoTrack, Inc.Healthcare

$2.02+$2.09

+92.9%

NASDAQ · Mkt cap $3.7 M

GlucoTrack CEO Erik Emerson announced strategic updates on LT-100 progress and ai² platform growth on September 23, positioning the company's drug development and monetization strategy, likely triggering the sharp rally as investors reacted positively to the clinical and commercial roadmap.

Two press releases from Lōkahi Therapeutics (GlucoTrack's parent or partner entity) arrived on September 23, both highlighting forward progress. The first announced advancement of the proprietary ai² PIPELINE process from an internal asset engine to a revenue-generating platform, suggesting commercialization of their drug discovery technology. The second provided a strategic update from CEO Erik Emerson covering LT-100 clinical progress, ai² platform expansion, and a structured strategy to discover, advance, and monetize assets. For a micro-cap biotech stock trading at $2.02, news of clinical advancement and a clear path to revenue generation can trigger outsized percentage gains, especially if prior sentiment was depressed. The 93% single-day jump suggests investors interpreted these announcements as material validation of the company's pipeline and business model.

CUEN

Cuentas Inc.Technology

$0.63+$0.23

+57.4%

NASDAQ · Mkt cap $5.4 M

No news headlines were found in the last 48 hours, so the 57% jump in CUEN cannot be attributed to a specific reported event; the move likely reflects technical trading, delayed news dissemination, or market microstructure effects in a low-priced stock.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to connect this substantial gain to a concrete catalyst such as earnings, guidance, a contract win, or strategic announcement. For micro-cap stocks trading under $1, price moves of this magnitude can occur from several sources: delayed reporting of news that may have circulated through other channels, short covering in a lightly traded security, retail or algorithmic buying pressure, or shifts in sentiment unrelated to company fundamentals. Without access to real-time trading data, SEC filings, press releases issued outside the RSS feed, or social media signals, any specific cause remains speculative. The rank as the number two gainer suggests broad market interest, but the lack of corroborating news limits confidence in identifying what drove it.

BFRG

Bullfrog AI Holdings, Inc. Common Stock

$0.93+$0.33

+55.0%

QUMSR

Quantumsphere Acquisition Corp. Rights

$0.09+$0.03

+48.8%

GCDT

Green Circle Decarbonize Technology LimitedIndustrials

$0.50+$0.16

+47.3%

NYSE · Mkt cap $5.2 M

Green Circle Decarbonize announced a 1-for-6 share consolidation effective October 7, 2026, which likely triggered the 47% intraday jump as consolidations mechanically increase per-share price and often attract attention from traders positioned ahead of the event.

A 1-for-6 reverse stock split consolidates six existing shares into one new share, mechanically raising the price per share by approximately six-fold on an ex-date basis. The stock closed at $0.50 today, suggesting pre-consolidation trading. Reverse splits often prompt trading activity from multiple sources: traders covering short positions, index funds rebalancing to avoid delisting thresholds, retail attention to the announcement, and positioning ahead of the ex-date. The stock's extremely low price and listing on NYSE American suggests it may have been at risk of delisting rules; the consolidation is a common remedial action. The 47% single-day move is consistent with consolidation announcement volatility, though the precise split between consolidation mechanics and underlying trading dynamics cannot be fully isolated from the data provided.

CHPGR

ChampionsGate Acquisition Corporation Rights

$0.16+$0.05

+47.2%

NASDAQ

No news headlines were found in the last 48 hours, so the 47% rally in this SPAC rights vehicle likely reflects either a technical or structural catalyst unrelated to public announcements, or delayed market reaction to earlier events.

ChampionsGate Acquisition Corporation Rights is a SPAC-related security, and these instruments are often thinly traded with volatile percentage swings on modest absolute share movement. The absence of any news in the 48-hour window prior to this snapshot does not rule out a catalyst occurring earlier or a technical rebound from oversold conditions. Possible drivers include renewed optimism about the underlying merger or business combination, short covering in a low-liquidity name, or investor rotation back into de-SPAC plays. Rights offerings are particularly sensitive to speculation about redemption rates and deal completion timing. Without a specific headline or announcement, however, any explanation remains speculative and grounded in the structural characteristics of SPAC rights rather than a concrete news event.

EONR.WT

EON Resources Inc WT

$0.11+$0.03

+46.5%

VTGN

VistaGen Therapeutics IncHealthcare

$0.36+$0.11

+42.5%

NASDAQ · Mkt cap $11 M

VistaGen announced preliminary positive data from the open-label extension of its Phase 3 PALISADE-4 trial for Fasedienol in social anxiety disorder, showing good tolerability and clinical improvement, driving the 42% gain.

The headline establishes that VistaGen released favorable Phase 3 extension data for its lead candidate Fasedienol nasal spray on September 22. The announcement highlights two key points: no new safety concerns after up to 12 months of as-needed use, and clinically relevant improvement in social anxiety symptoms. For a clinical-stage biotech stock, positive Phase 3 data—especially safety and efficacy signals in a large mental health market—typically drives substantial single-day rallies, particularly if the stock had been under pressure or if the data exceeded market expectations. The timing (announcement the day before the 42% jump) and rank as the eighth-biggest gainer suggest broad market recognition of the positive catalyst. Without access to prior guidance or consensus expectations, we cannot quantify whether this beat or met expectations, but the magnitude of the move is consistent with a meaningful de-risking event for a company developing a novel acute-use nasal therapy.

TJGC

TJGC Group LimitedCommunication Services

$23.37+$6.94

+41.1%

NASDAQ · Mkt cap $44 M

No news headlines were found in the last 48 hours for TJGC, so the 41% gain likely reflects either delayed news dissemination, a technical/sentiment driver, or an untracked company announcement.

The complete absence of recent news in the RSS feed is notable given the magnitude of the move. A 41% single-day surge in a small-cap stock like TJGC Group Limited typically requires a catalyst, but that catalyst is not visible in the provided headline data. This could indicate several possibilities: the news broke but has not yet appeared in the Yahoo Finance RSS feed used here, the move is driven by technical factors such as short-covering or options expiry effects, or an announcement was made through channels not captured by this feed. Small-cap stocks are also more prone to sentiment shifts and retail trading activity. Without access to the company's investor relations page, press releases, or real-time market data, attributing the move to a specific event would be speculation.

ARTL

Artelo Biosciences IncHealthcare

$7.30+$1.63

+39.6%

NASDAQ · Mkt cap $3.3 M

Artelo Biosciences filed a provisional patent for ART27.13 showing promising nonclinical weight-loss data in obese mice, achieving approximately 40% weight reduction combined with semaglutide, driving the 39.63% stock surge.

The company announced a new provisional patent application covering ART27.13 for obesity treatment, with the headline highlighting unexpected nonclinical findings. The specific data points—40% weight loss in combination with semaglutide and 20% as monotherapy in mice—represent material progress in a high-value therapeutic area where GLP-1 drugs have generated enormous market interest. For a small biotech company, a patent filing combined with positive preclinical efficacy data suggesting synergy with an established weight-loss drug class is a meaningful catalyst. The combination strategy angle is particularly notable because it suggests potential commercial positioning alongside the blockbuster GLP-1 market. While preclinical mouse data does not guarantee clinical efficacy or regulatory approval, the market appears to have interpreted this as validation of the scientific approach and intellectual property protection for a promising mechanism.

MSS

Maison Solutions Inc. - Class A Common StockConsumer Defensive

$2.10+$0.57

+36.8%

NASDAQ · Mkt cap $1.6 M

No news headlines were found in the last 48 hours for MSS, so the 36.81% gain likely reflects technical trading, a delayed announcement, or market rumors not yet captured by news feeds.

The absence of any headlines in the Yahoo Finance RSS for the past two days makes it impossible to attribute MSS's sharp 36.81% single-day gain to a specific corporate event such as earnings, guidance, acquisition news, or regulatory approval. For a micro-cap or thinly traded stock like this, large percentage moves can result from several categories: technical factors such as short covering or options-driven hedging adjustments, retail trading volume spikes on social media, sector rotation into small-cap equities, or company announcements that have not yet been indexed by mainstream news aggregators. The stock's rank as the 11th biggest gainer suggests this was a genuine intraday move, not a data error, but without corroborating headlines or structural context about the company, the specific catalyst remains opaque.

VRME

VerifyMe, Inc.

$1.14+$0.37

+35.2%

ONCO

Onconetix, Inc.Healthcare

$0.91+$0.23

+33.0%

NASDAQ · Mkt cap $2.8 M

No news headlines were found in the last 48 hours, so the 33% jump is likely driven by technical factors, a delayed market reaction to an earlier announcement, or retail trading activity rather than a fresh fundamental catalyst.

The absence of recent headlines is the most striking fact here. A 33% single-day gain that ranks in the top 13 gainers would normally correspond to meaningful news—an FDA approval, earnings surprise, partnership announcement, or guidance raise. That nothing appears in the Yahoo Finance RSS feed for the past 48 hours suggests either the catalyst predates that window, or the move is driven by non-news factors. For a micro-cap biotech stock trading near $1, common catalysts include short-squeeze dynamics, retail attention on social platforms, technical break-outs above resistance levels, or delayed digestion of clinical trial results posted earlier in the week. Without access to the specific driver, any explanation beyond "something moved the stock" remains speculative.

PGACR

$0.17+$0.04

+31.0%

XXII

22nd Century Group IncConsumer Defensive

$2.34+$0.53

+29.4%

NASDAQ · Mkt cap $1.4 M

No news headlines were found in the last 48 hours, so the 29.43% gain likely reflects technical trading, a delayed announcement, or sector-specific momentum in biotech or tobacco-alternative stocks rather than a clearly identified catalyst.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for the 29.43% jump. 22nd Century Group operates in the reduced-risk tobacco and cannabis space, sectors prone to sudden momentum shifts driven by regulatory developments, clinical trial results, or industry sentiment changes that may not immediately appear in headline feeds. Given the stock's position as 15 largest gainer today, the move could reflect short covering on a heavily shorted name, a delayed press release not yet indexed by the RSS feed, technical breakout trading, or sector-wide tailwinds in the cannabis or harm-reduction tobacco category. Without corroborating news, these remain hypotheses rather than confirmed causes. The timing and magnitude suggest a discrete event rather than gradual sentiment drift.

NCPL

Netcapital Inc.Financial Services

$1.08+$0.27

+29.0%

NASDAQ · Mkt cap $1.8 M

No news headlines were found in the last 48 hours for NCPL, so the 29% gain on September 23 appears driven by factors other than reported corporate announcements, earnings, or major events.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for the 28.96% jump. Netcapital is a micro-cap stock trading at $1.08, and such stocks are often sensitive to technical factors, short covering, social media attention, or broader market sentiment shifts that may not immediately appear in major financial news feeds. Possible categories of drivers include a delayed news story not yet indexed by Yahoo Finance RSS, insider buying or offering news released after hours, Reddit or retail trader interest, short squeeze activity, or movement tied to broader fintech or crowdfunding sector rotation. Without headlines or structural details about NCPL's capital structure or recent trading patterns, however, the specific cause remains speculative.

HVIIR

Hennessy Capital Investment Corp. VII Rights

$0.36+$0.08

+28.3%

IOTR

iOThree Limited Ordinary SharesCommunication Services

$2.08+$0.43

+26.0%

NASDAQ · Mkt cap $13 M

No news headlines were found in the last 48 hours to explain the 26% gain. The jump likely reflects a technical bounce, delayed reaction to an earlier event, or undisclosed catalyst not yet picked up by major financial news feeds.

iOThree (IOTR) gained 25.98% on September 23, 2026, to reach $2.08 per share, ranking among the day's top gainers. However, no recent news headlines are available from the past 48 hours on Yahoo Finance to account for this move. When a small-cap stock moves sharply on light or absent public news flow, the cause typically falls into several categories: a technical rebound after oversold conditions, insider or early-stage rumors not yet widely reported, short-covering activity if the stock had elevated short interest, a delayed reaction to an earlier press release or earnings report, or announcement via channels not immediately captured by mainstream financial news aggregators. Without access to company filings, earnings reports, or industry-specific news sources, identifying the precise catalyst is not possible from the available evidence.

FLZH

Flash Sports & Media Holdings, Inc.Communication Services

$0.08+$0.01

+24.4%

NASDAQ · Mkt cap $60 M

No news headlines were found in the last 48 hours, so the 24.39% gain on FLZH stock likely reflects technical trading, delayed news dissemination, or speculative activity in a low-priced security.

The absence of any recent news headlines makes it impossible to identify a specific corporate catalyst for the jump. FLZH is a micro-cap stock trading at eight cents, a price point that often attracts retail traders and can exhibit outsized volatility on modest volume. The gain could stem from several sources: a delayed market reaction to older news not captured in the 48-hour window, technical buying or short covering, social media chatter, or a rumor circulating outside formal news channels. Micro-cap securities are also prone to promotional activity or simple rebalancing of small positions. Without confirmed news or structural insight into the company's recent announcements, earnings, or shareholder events, pinpointing the driver is speculative.

DCOY

Decoy Therapeutics IncHealthcare

$3.83+$0.73

+23.6%

KFIIR

K&F Growth Acquisition Corp. II Rights

$0.11+$0.02

+22.1%

NASDAQ

No news headlines were found in the last 48 hours, so the 22% gain in KFIIR (a SPAC rights unit) likely reflects either a delayed market reaction to an earlier announcement, technical rebalancing, or speculative positioning typical of low-priced blank-check securities.

The absence of recent news makes direct attribution impossible. However, KFIIR is a rights offering tied to K&F Growth Acquisition Corp. II, a special purpose acquisition company. SPAC-related securities often exhibit outsized volatility on thin trading volumes and can spike on speculation about merger timelines, target company rumors, or technical factors unrelated to fundamental news. The 22% jump on no identifiable headline suggests either a delayed reaction to an earlier announcement not captured in the 48-hour window, algorithmic or retail momentum trading in a micro-cap security, or an internal corporate development (shareholder vote, merger timeline update) that has not yet reached major financial news outlets. Without additional context on KFIIR's recent corporate history or trading patterns, we cannot confidently isolate the cause.

AIXC

Aixcrypto Holdings IncTechnology

$1.68+$0.30

+21.7%

QNC

Quantum eMotion Corp.

$2.03+$0.36

+21.1%

GPACW

Global Partner Acquisition Corp II

$0.22+$0.04

+20.7%

APUS

Apimeds Pharmaceuticals US, IncHealthcare

$2.26+$0.39

+20.5%

NYSE · Mkt cap $6.0 M

No news headlines were found in the last 48 hours, so the 20.54% gain cannot be directly attributed to a disclosed catalyst; the move likely reflects a technical or rumor-driven event common to small-cap pharma stocks.

Yahoo Finance returned no headlines for APUS in the past two days, which means no earnings release, FDA decision, clinical trial result, partnership, or guidance change can be confirmed as the driver. APUS is a small-cap pharmaceutical company, and such stocks are prone to sharp intraday swings on minimal volume, short-covering rallies, social media activity, or undisclosed company announcements that may not yet be indexed by major news feeds. Without access to SEC filings, press releases, or trading volume context, it is impossible to determine whether this is a fundamental repricing or a technical event. The most likely categories are a delayed press release not yet picked up by RSS, a short squeeze on low float, or early investor reaction to a pre-announced event.

DBGI

Digital Brands Group, Inc.Consumer Cyclical

$5.69+$0.95

+20.4%

NASDAQ · Mkt cap $6.8 M

No news headlines were found in the last 48 hours for DBGI, so the 20.38% gain on September 23 cannot be attributed to a specific announced event. The move likely reflects either a delayed market reaction to earlier news, technical trading, or untracked developments.

Digital Brands Group is a small-cap apparel and fashion company listed on NASDAQ, and a 20.38% single-day jump with no accompanying news is not uncommon for stocks of this size. Small-cap stocks are prone to sharp moves on thin trading volume, short covering, or delayed reactions to company announcements that may not have been immediately picked up by major news aggregators. Without access to press releases directly from the company, SEC filings, or social media announcements made on September 23 itself, we cannot isolate a specific catalyst. The move could reflect positive earnings or guidance if released that day, analyst upgrades, insider buying, or simply technical momentum in a thinly traded name. Alternatively, external factors like sector rotation in retail or fashion could have provided tailwinds.

CVKD

Cadrenal Therapeutics, Inc.Healthcare

$1.32+$0.22

+20.0%

NASDAQ · Mkt cap $5.9 M

Cadrenal Therapeutics announced participation in the Lytham Partners Fall 2026 Investor Conference, a modest corporate event that likely triggered modest buying interest in this small-cap biotech stock, though the +20% gain suggests investors may be responding to renewed visibility or broader sec…

The only headline provided announces Cadrenal's participation in an investor conference scheduled for the fall of 2026. This is a routine corporate event notification, not a clinical result, regulatory approval, financing announcement, or product milestone. For a late-stage biopharmaceutical company trading at $1.32, a +20% single-day jump on conference participation alone would be atypical unless it reflects either pent-up investor demand from a period of neglect, technical short-covering, or market-wide momentum in the sector. The headline does not establish why the stock moved; it only establishes that the company communicated an upcoming investor meeting. Without additional context on recent performance, analyst coverage changes, or sector catalysts, the gap between the news (routine) and the move (substantial) remains unexplained.

BEAGR

Bold Eagle Acquisition Corp. Right

$0.24+$0.04

+20.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 20% gain in BEAGR is likely driven by technical trading, a delayed announcement, or typical SPAC-related activity rather than a specific corporate event.

Bold Eagle Acquisition Corp. Right (BEAGR) is a SPAC rights unit, a security type that can exhibit significant intraday volatility independent of company-specific news. The absence of any headlines in the last 48 hours rules out earnings surprises, regulatory actions, or merger announcements as documented causes. For a rights offering on a SPAC, gains of this magnitude often reflect technical factors such as short covering, options-driven demand, or shifts in sentiment toward the underlying SPAC or its target company if a deal is pending. Rights are leverage instruments and can amplify moves in the parent security. Without access to SPAC filing calendars or options data, the specific trigger cannot be pinpointed, but warrant or rights offerings frequently see trading surges around key dates or ahead of announced milestones.

GLND

Greenland Energy CompanyEnergy

$2.91+$0.46

+18.9%

NASDAQ · Mkt cap $62 M

President Trump's security deal with Greenland announced on September 21 boosted investor interest in Greenland-linked rare earth and critical metals stocks, with GLND gaining 18.85% as part of the broader sector rally triggered by anticipated supply chain opportunities.

The two headlines directly reference a Trump security pact with Greenland announced on September 21 that lifted Greenland-related stocks. The second headline explicitly notes that Critical Metals surged 38% following the announcement, establishing a clear sector-wide rally pattern. The first headline contextualizes this by citing the rare earth elements market growth projection of 8.6% CAGR through 2030, suggesting investors view the deal as positioning Greenland-linked companies to capture a portion of that $2.33 billion growth opportunity. While the exact terms of the security deal and GLND's specific operational exposure to Greenland are not detailed in the provided headlines, the timing of the 18.85% jump on September 23 aligns directly with the September 21 announcement, indicating investor interpretation that the deal creates favorable conditions for rare earth or critical metals companies operating or positioned in that region.

AIFU

Fanhua Inc.Financial Services

$9.92+$1.55

+18.5%

NASDAQ · Mkt cap $74 M

No news headlines were found in the last 48 hours, so the 18.52% gain likely reflects either delayed market reaction to an earlier announcement, short-covering, technical momentum, or untracked company-specific developments.

Fanhua Inc. (AIFU) jumped 18.52% to $9.92 on September 23 with no identifiable news in the last 48 hours according to available sources. This suggests either a lag between actual news release and RSS pickup, or a non-news catalyst. For a NASDAQ-listed education and fintech services company, typical catalysts include quarterly earnings surprises, enrollment beat announcements, strategic partnerships, regulatory clarity in China operations, or short-squeeze mechanics if the stock carries elevated short interest. Without headlines, we cannot determine which drove this move. The absence of news does not rule out an announcement made outside the monitored news feed window, nor does it exclude technical or sentiment-driven trading.

TLSA

Tiziana Life Sciences PLC

$1.05+$0.16

+18.0%

REBN

Reborn Coffee, Inc.Consumer Cyclical

$1.09+$0.17

+18.0%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours for REBN, so the 17.97% gain likely reflects technical trading, a delayed market reaction to an older announcement, or untracked social media momentum in a low-priced speculative stock.

The absence of recent news headlines makes it impossible to identify a specific catalyst for today's 17.97% jump in REBN stock. Reborn Coffee is a micro-cap equity trading at $1.09, a price range that often attracts retail interest and can exhibit outsized percentage moves on modest absolute volume. Possible explanations include technical bounce-back from recent weakness, a rumor or social media campaign not yet captured in major financial news feeds, delayed market pricing of an older announcement, or simply low-liquidity volatility. Without access to trading data, insider activity, or social media signals, a definitive cause cannot be established from the information provided.

SMJF

SMJ International Holdings Inc.Consumer Cyclical

$1.57+$0.23

+17.8%

HEPA

Hepion Pharmaceuticals IncHealthcare

$0.07+$0.01

+17.8%

NASDAQ · Mkt cap $5.5 M

No news headlines were found in the last 48 hours, so the 17.75% gain in HEPA stock is unexplained by reported corporate events. The move likely reflects technical buying, delayed news dissemination, or speculation in a low-price biotech stock.

The absence of any news headlines in the Yahoo Finance RSS for the past 48 hours makes it impossible to tie the 17.75% gain to a specific corporate catalyst. HEPA is a small-cap biotech company trading at $0.07, a price point typically associated with penny stocks that experience volatile moves on minimal volume or delayed information. Possible explanations, though speculative without evidence, include a technical bounce from oversold conditions, retail interest in low-priced securities, a clinical trial update or partnership announcement not yet widely distributed through mainstream financial news feeds, or general sector rotation into biotech. The company's pipeline and clinical status would be relevant to assess the move's merit, but that information is not provided in the available headlines. Without corroborating news, attributing the gain to fundamental developments is not warranted.

INVZ

Innoviz Technologies Ltd.Consumer Cyclical

$0.41+$0.06

+17.7%

NASDAQ · Mkt cap $107 M

No news headlines were found in the last 48 hours, so the 17.70% gain cannot be attributed to a specific announced catalyst. The move is likely driven by technical trading, sentiment shifts, or market rumors not captured in major news feeds.

Innoviz Technologies is a lidar and autonomous driving technology company, and such hardware/semiconductor-adjacent stocks can experience sharp intraday moves on minimal or no news due to their typically low float, retail interest, and sensitivity to sector sentiment. With no substantive headlines provided, the gain could reflect several possibilities: a technical bounce from oversold conditions, short covering given the stock's presumably low price point, positive commentary or rumors circulating on social platforms or trading forums not yet reflected in official news sources, or a delayed market reaction to older announcements. Without access to trading volume, short interest data, or detailed intraday activity, we cannot determine which factor drove this particular move.

PAAI

Arena Group Holdings Inc

$1.53+$0.23

+17.7%

ZKIN

ZK International Group Co LtdBasic Materials

$1.70+$0.25

+17.2%

NASDAQ · Mkt cap $58 M

No news headlines were reported in the last 48 hours for ZKIN, so the 17.24% gain cannot be directly attributed to any announced company event or market development.

The absence of recent news makes it difficult to pinpoint a specific catalyst for ZK International's 17.24% jump to $1.70. Possible explanations include delayed or non-simultaneous reporting of company announcements, a technical rebound in a historically volatile micro-cap stock, short covering or momentum buying, or broader sector rotation that has not yet been captured in headline feeds. ZK International operates in the steel and infrastructure space, so cyclical improvements in construction spending or commodity prices could theoretically drive moves, but without concrete news linking those factors to ZKIN specifically, this remains speculative. Another possibility is after-hours news or an announcement made through channels other than standard financial wire services that have not yet propagated to the Yahoo Finance feed.

FLYE

International Jet Engine Supply, Inc.Consumer Cyclical

$1.54+$0.21

+15.8%

NASDAQ · Mkt cap $2.9 M

No news headlines were published in the last 48 hours regarding FLYE, so the 15.79% gain cannot be directly attributed to a disclosed company announcement or event.

The absence of recent news coverage is the first constraint here. A 15.79% single-day jump in a micro-cap stock like FLYE can stem from several typical categories: a delayed or embargoed announcement not yet picked up by major RSS feeds, short-squeeze activity if the stock has high short interest, sector-wide tailwinds in aerospace or engine supply, insider trading signals, or technical momentum in thinly traded securities. International Jet Engine Supply operates in aerospace and defense, a sector that does respond to geopolitical events, defense spending announcements, or contract wins, but without confirming headlines, none of these can be established as the actual trigger. The lack of news is notable enough that either the catalyst has not yet been widely reported, occurred through unofficial channels, or the move reflects technical or sentiment factors independent of fundamental disclosure.

DTSQR

DT Cloud Star Acquisition Corporation Right

$0.15+$0.02

+15.5%

NASDAQ

No news headlines were found in the last 48 hours, so the 15.47% gain cannot be attributed to a specific announced event. The move likely reflects either technical trading activity, a delayed market reaction to an earlier announcement, or speculative positioning in a low-price SPAC-related security.

DTSQR is a rights offering associated with a SPAC (special purpose acquisition company) structure, a security class known for volatile intraday trading driven by arbitrage, warrant/right conversions, and retail speculation rather than fundamental news flow. The absence of headlines in the Yahoo Finance RSS feed does not necessarily mean no catalyst exists; it may indicate that relevant information was released via other channels, through a press release not yet syndicated widely, or that the move reflects technical factors such as options expiration, rebalancing, or short-covering in a thinly traded micro-cap security. Rights offerings in particular can experience sharp moves as merger timelines approach or as the underlying SPAC announces definitive agreements. Without access to SEC filings, company press releases, or broader market commentary, the specific driver cannot be identified from the provided evidence.

NNBR

NN IncIndustrials

$3.86+$0.52

+15.4%

NASDAQ · Mkt cap $322 M

NN Inc raised full-year 2026 guidance ranges for net sales and adjusted EBITDA on September 22, triggering a 15-16% rally in the stock the following morning as investors repriced the company's profit outlook upward.

On September 22, NN Inc announced a raise to its full-year 2026 guidance for both net sales and adjusted EBITDA. This is a classic positive catalyst for industrial components suppliers, signaling management confidence in accelerating demand and operational execution. The headline from September 23 confirms the stock jumped approximately 16% in the morning session immediately following the announcement. Guidance raises typically drive equity appreciation because they reset market expectations and demonstrate that company leadership believes conditions have improved enough to warrant higher targets. For a precision manufacturing business, such a move suggests either stronger customer demand, better-than-expected operational efficiency, or both. No conflicting news or negative events are evident in the provided headlines, making the guidance raise the clear and direct cause of the move.

LKSPR

Lake Superior Acquisition Corp. Rights - For Shares

$1.15+$0.15

+15.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 15% gain appears driven by technical or market-structure factors typical of SPAC rights offerings rather than a specific corporate event.

Lake Superior Acquisition Corp. Rights (LKSPR) is a SPAC rights security, which grants holders the ability to purchase shares of the underlying SPAC at a set price. These instruments are highly sensitive to the status and timeline of the SPAC's merger or liquidation process. With no recent news provided, the move is most likely attributable to one of two factors: either a technical rebound in the SPAC warrant or rights market more broadly, or renewed investor interest in the underlying SPAC's merger timeline or target. SPAC rights can experience sharp moves on relatively light volume when sentiment around deal closure shifts or when broader SPAC sentiment rebounds. Without a specific headline, we cannot rule out a delayed announcement effect or simply a repositioning within the SPAC complex.

EGHT

8x8 IncTechnology

$2.30+$0.30

+15.0%

NASDAQ · Mkt cap $303 M

No news headlines were found in the last 48 hours for EGHT, so the 15% gain likely reflects either delayed market reaction to an earlier announcement, technical/short-covering activity, or an untracked catalyst.

The absence of any news in the Yahoo Finance RSS feed over the past two days makes it difficult to pinpoint a specific fundamental catalyst for EGHT's sharp 15% single-day jump. 8x8 Inc is a cloud communications and UCaaS provider, so typical catalysts for this sector include earnings surprises, contract wins, guidance revisions, or strategic partnerships. Given the stock's relatively modest price point of $2.30, it may be more susceptible to short-covering rallies or technical breakouts on modest volume. It is also possible that news was announced earlier than the 48-hour window, or that the market is reacting to sector-wide developments in enterprise software or communications platforms that have not yet been covered in major headlines. Without access to the actual catalyst, we cannot definitively explain this move.

COSM

Cosmos Holdings Inc.Healthcare

$0.41+$0.05

+14.9%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours, so the 14.94% gain on COSM cannot be attributed to a confirmed recent announcement or event based on available RSS data.

The absence of news in Yahoo Finance's RSS feed over the past 48 hours means we cannot identify a specific catalyst from headline-based sources. A micro-cap stock like COSM trading at $0.41 can experience sharp intraday moves from several categories of events: technical rebounds after oversold conditions, delayed disclosure of company announcements not yet picked up by major news feeds, social media or retail trading momentum, sector rotation, or intraday algorithmic trading patterns. Without access to the company's investor relations page, SEC filings from today, or OTC market data specifics, it is not possible to confirm whether the move reflects new fundamental information or market technicals. The lack of coverage in major RSS feeds suggests either the move was entirely technical in nature or that news exists but has not yet been syndicated.

WAFU

Wah Fu Education Group LtdConsumer Defensive

$1.59+$0.20

+14.4%

NASDAQ · Mkt cap $6.3 M

No news headlines were published in the last 48 hours, so the 14.39% gain cannot be attributed to a confirmed catalyst. The move likely reflects technical trading, delayed market reactions to earlier announcements, or unconfirmed rumors.

The absence of any Yahoo Finance headlines in the last 48 hours means we cannot point to a specific corporate event, earnings report, regulatory decision, or guidance change as the driver of this gain. WAFU is a small-cap education stock trading at $1.59, a price point where stocks are often subject to high volatility and can be influenced by retail interest, short covering, or technical momentum. Possible explanations include a delayed market reaction to news from earlier in the week that has not yet cycled through the headline feed, momentum trading off a previous bottom, or unconfirmed rumors circulating on social platforms. Without corroborating news, we cannot distinguish between a fundamental catalyst and purely technical or sentiment-driven movement.

HKIT

Hitek Global Inc.Technology

$2.81+$0.35

+14.0%

NASDAQ · Mkt cap $27 M

No news headlines were found in the last 48 hours for HKIT, so the 14% rally on September 23 cannot be attributed to a disclosed event or announcement. The cause remains unknown without access to intraday trading data or social media activity.

The absence of any Yahoo Finance headlines in the last 48 hours is notable for a stock that ranked 45th in daily gainers. This gap suggests either that the catalyst was not captured by standard news feeds, or that it originated from sources outside traditional financial media. For a microcap or lower-liquidity stock like HKIT, possible drivers of a 14% single-day move without headline coverage include technical rebound from oversold conditions, retail trading activity on social platforms, insider buying or other form signaling, or delayed market reaction to a pre-existing announcement. Without visibility into order flow, short interest levels, or the stock's historical volatility, attributing this move to any specific category would be speculative.

YDES

YD BIO LIMITEDHealthcare

$3.27+$0.40

+13.9%

NASDAQ · Mkt cap $317 M

No news headlines were found in the last 48 hours for YDES, so the 13.94% intraday gain cannot be attributed to a publicly reported catalyst. The move likely reflects technical trading, delayed news, or sector-wide momentum.

YD Bio Limited showed a strong single-day gain ranking it among the top 50 gainers on NASDAQ, yet no recent news was available through Yahoo Finance RSS in the prior 48 hours. This disconnect suggests either the catalyst has not yet been widely reported, the move was driven by technical factors such as short covering or options-related hedging, or the stock responded to sector momentum unrelated to company-specific fundamentals. Biotech and small-cap stocks like YDES can experience outsized intraday swings on low volume without accompanying news flow. Without access to earnings announcements, clinical trial results, regulatory filings, or institutional news wires that might have been released, attributing causation to a specific event would be speculation.

KOSS

Koss Corp

$3.98+$0.48

+13.7%

CBAT

CBAK Energy Technology IncIndustrials

$1.47+$0.18

+13.6%

NASDAQ · Mkt cap $62 M

CBAK Energy announced a major 12 GWh sodium-ion battery project investment agreement in Nanjing on September 23, which likely drove the 13.57% gain as it signals substantial capacity expansion and revenue growth potential.

The company released a concrete announcement of a new investment agreement for a 12 GWh sodium-ion battery manufacturing facility in Nanjing, with an additional planned 6 GWh expansion by year-end 2026 that would more than double the existing facility's capacity. This is a material corporate development indicating significant capital commitments and future production scale-up in a high-demand battery segment. The timing of the announcement on the same day as the price jump, combined with CBAK's status as a penny stock with volatile trading patterns, suggests the market responded positively to the growth signal. The separate news item mentioning inflation and rate concerns appears generic and unlikely to be the primary driver of this specific stock's move.

SRFM

Surf Air Mobility Inc. Common StockIndustrials

$0.87+$0.10

+13.3%

NYSE · Mkt cap $85 M

Surf Air Mobility jumped 13.27% after announcing a definitive OperatorOS contract with SkyDance Air and appointing Barrett Brown as President of SurfOS, signaling strategic commercial traction and leadership strengthening.

Two material announcements on the morning of September 23rd likely drove the gain. The company signed a definitive agreement with SkyDance Air to deploy its OperatorOS platform, which appears to be a core software product for air mobility operators. Simultaneously, Surf Air appointed Barrett Brown to lead SurfOS, suggesting internal organizational focus on its software division. For a company in the nascent air mobility sector, concrete customer contracts and leadership appointments that suggest operational execution are typically viewed as derisking events. The stock's low absolute price and status as a top gainer suggest it may be held by retail or speculative investors responsive to headline news of commercial progress.

MYSZ

My Size IncConsumer Cyclical

$1.88+$0.22

+13.0%

NASDAQ · Mkt cap $1.7 M

No news headlines were reported in the last 48 hours for MYSZ, so the 12.95% gain on September 23 cannot be attributed to a specific announced event. The move is likely driven by technical factors, retail interest, or unreported developments.

My Size Inc saw a significant single-day rally of nearly 13% to reach $1.88, ranking it among the top 50 gainers on NASDAQ for the day. However, no news headlines appear in the Yahoo Finance RSS feed for the prior 48-hour window, which creates a clear gap between the price action and publicly available information. For a micro-cap stock like MYSZ, typical catalysts could include clinical or operational updates, partnership announcements, insider accumulation, or short-squeeze dynamics, but none of these are confirmed by the evidence provided. The absence of headlines does not rule out news distribution through other channels, private disclosure, or simply that the catalyst has not yet been widely reported by financial media.

Biggest Losers

Wed, Sep 23, 2026 50

ARCI

Appliance Recycling Centers of America IncFinancial Services

$0.55−$9.55

-94.5%

JAGX

Jaguar Health IncHealthcare

$9.01−$28.30

-77.5%

NASDAQ · Mkt cap $4.5 M

Jaguar Health collapsed 77.53% despite premarket gains and positive FDA news, suggesting a major negative catalyst emerged during market hours that overwhelmed earlier optimism about its MVID development program.

The timeline reveals a striking disconnect. On the morning of September 23, JAGX soared over 10% in premarket trading following what appears to be positive momentum and FDA fee waivers announced the prior day. However, by the close, the stock had reversed catastrophically to a 77.53% loss, making it the second-biggest loser of the day. The headlines provided do not identify a specific negative catalyst released during market hours. The FDA fee waiver and the mid-2027 NDA filing target for crofelemer powder both appear supportive of the company's rare disease program. For a biotech stock of this profile, such a violent reversal typically follows material clinical trial setbacks, safety concerns, unexpected regulatory feedback, significant dilution, leadership changes, or major financing shortfalls. The absence of a documented negative headline in the provided news feed suggests either that the market received adverse information not yet reflected in these RSS sources, or that existing investors capitalized on the premarket pop to exit positions in anticipation of or response to information in the full market.

ADGM

Adagio Medical Holdings, Inc Common StockHealthcare

$0.23−$0.25

-51.9%

NASDAQ · Mkt cap $14 M

Adagio Medical announced a strategic review process on September 23rd, which typically signals potential asset sales, restructuring, or other major corporate changes that often trigger sharp selling as investors fear dilution or unfavorable outcomes.

The headline announces a "Strategic Review Process to Maximize Shareholder Value," which is corporate language commonly associated with companies exploring alternatives including potential sales of assets or the entire business. Such announcements frequently prompt sharp declines because markets interpret them as signals of financial distress, upcoming dilution, or management inability to execute standalone strategy. The 51.89% single-day drop ranks this among the day's three worst performers, suggesting market participants viewed the announcement as materially negative. However, the headline snippet provided is incomplete—the full details of what triggered the review, whether there are time constraints, competing bidders, or guidance changes are not included in the available text. Without the complete announcement details or accompanying financial statements, we cannot rule out other concurrent negative catalysts such as disappointing operational results, guidance cuts, or other adverse developments released simultaneously.

HVII

Hennessy Capital Investment Corp. VII Ordinary Shares

$4.54−$4.45

-48.9%

ATXI

Avenue Therapeutics IncHealthcare

$0.25−$0.21

-45.7%

NASDAQ · Mkt cap $824 K

No news headlines were published in the last 48 hours for ATXI, so the 45.65% single-day drop cannot be attributed to a specific disclosed event. The cause remains unclear without additional reporting.

Avenue Therapeutics is a small-cap biopharmaceutical company, and the absence of news in the last 48 hours means we cannot anchor the decline to an earnings miss, clinical trial result, FDA decision, financing announcement, or other company-specific catalyst. For stocks in this category, sharp single-day losses typically reflect one of several possibilities: a delayed or embargoed news release that markets are front-running, sector-wide contagion in small-cap biotech, technical breakdown in a low-liquidity stock, short covering reversal, or private negative information circulating before public disclosure. The 45.65% magnitude suggests institutional or systematic selling rather than random noise. Without access to real-time trading data, SEC filings, or contemporaneous news wires beyond the RSS feed provided, pinpointing the trigger is not possible.

AFJKR

Aimei Health Technology Co., Ltd Right

$0.09−$0.04

-30.8%

IMCC

IM Cannabis Corp.Healthcare

$2.89−$1.26

-30.4%

NASDAQ · Mkt cap $1.1 M

IM Cannabis announced a $1.31 million registered direct offering of common shares on September 23, which typically triggers shareholder dilution concerns and explains the 30.39% single-day drop, despite simultaneously regaining Nasdaq compliance.

The company released three announcements on the same day: regaining Nasdaq minimum bid price compliance, pricing a $1.31 million registered direct offering, and entering a non-binding agreement to acquire 51% of a European drone company. While the Nasdaq compliance restoration is technically positive, the registered direct offering is a classic dilutive capital raise that signals either financial distress or aggressive capital needs. Investors typically sell on such dilution announcements because existing shareholders face immediate dilution and the offering often comes at a discount to the current market price. The attempted diversification into defense technology via Space Defense Innovations may have added uncertainty about strategic direction. The scale of the move (ranking 7 biggest loser) suggests the dilution concern combined with strategic uncertainty drove substantial institutional or algorithmic selling.

RPGL

Republic Power Group LimitedTechnology

$1.00−$0.43

-30.0%

NASDAQ · Mkt cap $2.6 M

Republic Power Group announced a 1-for-16 reverse share split effective today, which typically signals financial distress or NASDAQ compliance issues and triggered a sharp 30% sell-off as investors reassess the stock's fundamental weakness.

The reverse share split announcement is the only news event within 48 hours of this 29.97% decline. Reverse splits are commonly employed by companies facing delisting risk due to low share prices or when a stock has deteriorated significantly in value. While a reverse split mechanically consolidates shares and can temporarily lift the nominal price, markets typically view such actions negatively because they reflect underlying business problems rather than create value. The stock closing at exactly $1.00 after the split suggests the market is pricing in severe distress. The timing of the announcement coinciding with the major drop indicates investors are interpreting this as a distress signal rather than a positive strategic move, and the stock's position as the eighth biggest loser suggests broader selloff pressure or short positioning in response to the announcement.

DCX

Chijet Motor Company, Inc.Consumer Cyclical

$0.07−$0.03

-29.8%

NASDAQ · Mkt cap $322 M

No news headlines were found in the last 48 hours, so the 29.76% drop cannot be attributed to a specific announced catalyst; the move likely reflects technical selling, short covering reversal, or an unanticipated company-specific event not yet reported.

DCX experienced a severe single-day decline of nearly 30 percent, placing it among the top ten losers on NASDAQ, yet no news headlines from Yahoo Finance appear in the past 48 hours to explain the move. For a micro-cap stock trading at $0.07, declines of this magnitude are not uncommon and can be driven by several factors: thin liquidity causing rapid price swings on modest volume, a short squeeze unwinding after prior gains, technical breakdown below key support levels, or negative company developments that have not yet reached major financial news outlets but are known to retail traders or insiders. Without concrete reporting, attributing this move to earnings, guidance, litigation, financing news, or regulatory action would be speculation. The absence of news in a major aggregator like Yahoo Finance does not prove nothing happened, only that if something did, it has not been widely picked up by major outlets yet.

KLXER

KLX Energy Services Holdings, Inc. Rights

$0.00−$0.00

-27.3%

HUBC

Hub Cyber Security Ltd. - Ordinary SharesTechnology

$3.21−$1.16

-26.6%

NASDAQ · Mkt cap $23 M

No news headlines were found in the last 48 hours to explain the 26.61% drop in HUBC. The move likely reflects either a delayed market reaction to an earlier announcement, technical selling pressure, or undisclosed company-specific developments.

The absence of recent news makes it difficult to pinpoint the exact cause of this sharp decline. A drop of this magnitude in a small-cap cybersecurity stock typically follows material announcements such as earnings misses, guidance reductions, executive departures, contract losses, or disclosure of operational challenges. Without headline data, the move could reflect several scenarios: delayed market digestion of news released prior to the 48-hour window, a technical breakdown in a thinly traded name, broader sector weakness in cybersecurity stocks, or an internal development announced through direct company channels rather than newswire. Cybersecurity stocks are subject to investor sentiment shifts around competitive positioning, client concentration risk, and revenue growth deceleration.

IPDN

Professional Diversity Network IncIndustrials

$5.43−$1.66

-24.8%

NASDAQ · Mkt cap $2.7 M

No news headlines were available in the last 48 hours to explain IPDN's 24.77% drop, so the cause remains unclear; the move may reflect earnings disappointment, insider selling, sector weakness, or market speculation.

The absence of any headlines in the recent news feed makes it impossible to identify a specific catalyst for IPDN's steep single-day decline. Professional Diversity Network Inc is a small-cap NASDAQ stock, and stocks in this segment can experience outsized intraday swings on relatively modest volume or sentiment shifts. Without concrete information, the drop could stem from several broad categories: delayed disclosure of negative quarterly results or guidance revision, significant insider or secondary offering activity, deterioration in a key business relationship, broader market weakness in the HR technology or professional services sector, or speculative positioning that has reversed. The 24.77% magnitude is substantial enough to suggest real news rather than pure technicals, but confirmation requires either company disclosure or follow-up reporting.

KCAC.WT

$0.95−$0.31

-24.4%

MRNO

Murano Global Investments PLCReal Estate

$0.24−$0.07

-23.7%

NASDAQ · Mkt cap $19 M

No news headlines were found in the last 48 hours, so the 23.73% drop cannot be attributed to a specific announced event; the decline may reflect broader market weakness, technical selling, or an unannounced development.

With no headlines available from Yahoo Finance RSS in the past two days, there is no documented news catalyst to explain the significant 23.73% decline in MRNO. The stock trades at $0.24, suggesting it is a micro-cap or penny stock, a category prone to elevated volatility and liquidity constraints that can amplify intraday price swings. Possible causes include: (1) broad market or sector weakness that disproportionately affects lower-priced equities, (2) technical selling or momentum reversal following a prior rally, (3) a delayed or unannounced development not yet covered by major news outlets, or (4) low trading volume exaggerating the reported percentage loss. Without access to regulatory filings, earnings dates, insider transactions, or sector-specific events, distinguishing among these hypotheses is not possible from the available data.

CAPS

Capstone Therapeutics CorpBasic Materials

$0.20−$0.06

-23.6%

NASDAQ · Mkt cap $2.9 M

No news headlines were found in the last 48 hours, so the 23.6% drop cannot be attributed to a specific announced event. The decline likely stems from technical selling, market sentiment shifts, or unannounced company developments.

The absence of any news headlines in the Yahoo Finance RSS feed in the last 48 hours makes it impossible to pinpoint a specific catalyst for Capstone Therapeutics' sharp 23.6% decline on September 23, 2026. For a micro-cap stock trading at $0.20, typical drivers of large single-day drops include disappointing clinical trial results, failed FDA approvals or regulatory setbacks, cash runway concerns, leadership changes, or dilutive financing announcements. Small-cap biotech and therapeutics stocks are also highly sensitive to broader market movements, sector rotation, and technical support breaks. Without evidence of company-specific news, the move could reflect delayed disclosure of negative information, short-seller activity, or a technical breakdown in support levels common in low-priced equities.

GENVR

Gen Digital Inc. Contingent Value Rights

$1.93−$0.58

-23.0%

NASDAQ

GENVR fell 23% but the only headline provided is a generic Avast cybersecurity report unrelated to Gen Digital's financial performance, business developments, or CVR terms, suggesting the drop stems from undisclosed news or market mechanics tied to the contingent value rights structure itself.

The single headline about Avast's Safe Tech Report on deepfakes and data sharing appears to be a routine product/research announcement with no obvious negative implication for Gen Digital's business or valuation. CVRs are equity derivatives whose value depends heavily on the probability and timing of triggering events (typically merger-linked milestones or earnout conditions). A 23% single-day drop in a CVR is unusual and could reflect several possibilities: (1) news that the underlying triggering condition became less likely or delayed, (2) a structural change in the deal terms, (3) liquidity or technical factors typical of thinly traded contingent securities, or (4) a market announcement not captured in the provided headlines. Without access to the actual CVR prospectus, deal terms, or same-day corporate announcements from Gen Digital, the specific catalyst remains unclear.

WYTC

WYTEC INTERNATIONAL INC

$0.80−$0.23

-22.3%

NASDAQ

No news was reported in the last 48 hours. The 22% drop in WYTEC International likely reflects either a delayed market reaction to unreported company developments, sector weakness, or technical selling pressure among micro-cap stocks.

Yahoo Finance returned no headlines for WYTEC International in the 48 hours prior to this 22% decline, making it impossible to attribute the move to a specific named catalyst such as earnings, regulatory action, or strategic announcement. Micro-cap stocks trading at $0.80 often experience significant intraday volatility from technical factors like liquidity constraints, retail trading activity, or broader sector downturns that may not generate immediate news coverage. It is also possible that material information was released through other channels (company press release, SEC filing, or conference call) that has not yet appeared in Yahoo Finance's RSS feed, or that the market is reacting to events or rumors that predate the 48-hour window. Without accompanying headlines or known structural factors about WYTEC's business, capital structure, or market positioning, the specific driver remains speculative.

TOPS

TOP Ships IncEnergy

$0.69−$0.20

-22.3%

NYSE · Mkt cap $4.9 M

TOP Ships Inc. announced a response to unusual market action on September 22, but the headline text is incomplete, leaving the specific reason for the 22% drop unclear. The timing and size of the decline suggest a material event occurred.

The available headline from September 22 indicates that TOP Ships issued a statement responding to unusual market action, but the actual content of that response is not provided in the materials supplied. TOP Ships operates modern tanker vessels, a cyclical sector sensitive to shipping rates, fuel costs, and macroeconomic conditions. A 22% single-day drop combined with a company-issued response suggests something material occurred such as a warning about contract losses, unexpected impairment, vessel incident, regulatory action, or sharp downward guidance revision. Without the body of the company's statement, only the fact that management felt compelled to issue a public response can be confirmed. The drop ranks among the day's largest losers, indicating market-wide visibility of the negative catalyst.

CGEM

Cullinan Management, Inc.Healthcare

$16.86−$4.80

-22.2%

NASDAQ · Mkt cap $1.4 B

Cullinan Therapeutics (CGEM) fell 22.16% on September 23, tracking a broad biotech selloff that included Rapport Therapeutics and Climb Bio, though the provided headline does not specify a particular company-level catalyst for Cullinan itself.

The headline confirms that Cullinan Therapeutics was among the hardest-hit biotech names on Wednesday and explicitly states the selloff "had nothing to do with compelling, best-in-disease data," suggesting the decline was sector-wide rather than driven by trial results or clinical data from Cullinan specifically. The headline does not identify the underlying trigger for the biotech decline—whether macro weakness, regulatory concerns, market rotation, or an event affecting the sector broadly. Without additional reporting on what caused the sector move, we can infer that biotech stocks are responding to a common shock rather than Cullinan-specific news. Typical catalysts for sector-wide biotech declines include shifts in FDA policy, capital-markets tightening, changes in reimbursement expectations, or rotation out of growth stocks.

NFE

New Fortress Energy LLC

$6.39−$1.76

-21.6%

AACPR

Apogee Acquisition Corp Rights

$0.15−$0.04

-21.1%

RKDA

Arcadia Biosciences IncConsumer Defensive

$0.36−$0.09

-19.6%

NASDAQ · Mkt cap $964 K

No news headlines were found in the last 48 hours, so the 19.56% drop in RKDA likely reflects a delayed market reaction to an earlier announcement, technical selling, or sector-wide weakness unrelated to recent company-specific disclosure.

The absence of news in the 48-hour window preceding this significant single-day loss makes it difficult to pinpoint a definitive catalyst. RKDA is a small-cap biotech company, and such names are prone to sharp intraday moves on light volume, sector rotation, or delayed reactions to earnings or clinical trial results released outside the most recent news cycle. Without access to headlines from earlier in the week or today, the drop could stem from a negative development announced before the 48-hour snapshot window, broad biotech sector pressure, short covering, or technical breakdown through a support level. For micro-cap stocks like RKDA trading below $0.40, liquidity constraints can amplify price swings on relatively modest volume. The ranking as the 22nd biggest loser suggests this was part of a broader market move rather than isolated to one company-specific event.

NOTE

FiscalNote Holdings, Inc.Technology

$0.03−$0.01

-19.4%

NYSE · Mkt cap $2.0 M

No news headlines were found in the last 48 hours, so the 19.44% drop on NOTE appears driven by factors other than published company announcements or sector events.

The absence of recent news makes it difficult to pinpoint a specific catalyst for NOTE's sharp decline. FiscalNote is a government affairs and regulatory intelligence software company, and stocks in this category can be sensitive to several drivers: deteriorating underlying business metrics not yet announced, technical selling or algorithmic rebalancing, general equity market weakness, shifts in investor sentiment toward software or SaaS names, or delayed disclosure of contract losses or guidance cuts. Without access to intraday events, social media activity, or real-time market chatter, we cannot confirm which category applies. The stock's very low price of $0.03 also suggests it may be trading with wider bid-ask spreads and lower liquidity, which can amplify single-day moves on modest volume.

ALKT

Alkami Technology, Inc.

$14.60−$3.50

-19.3%

ZEO

ESGEN Acquisition Corporation

$0.40−$0.09

-19.2%

SLXN

Biomotion SciencesHealthcare

$0.32−$0.07

-17.7%

NASDAQ · Mkt cap $540 K

No news headlines were found in the last 48 hours, so the 17.74% decline cannot be directly attributed to a published event. The drop likely reflects either a delayed market reaction to earlier news, sector headwinds in biotech, or technical selling pressure.

The absence of recent news makes it difficult to pinpoint a specific catalyst for SLXN's sharp 17.74% decline. Biomotion Sciences is a small-cap biotech stock, and such names are highly sensitive to clinical trial results, regulatory decisions, funding announcements, and shifts in investor sentiment toward early-stage companies. Without headlines from the last 48 hours, the move could reflect any of several categories: a delayed market reaction to news released earlier in the week, broad sector weakness affecting small biotech names, short-selling or technical breakdown of a weak stock, adverse rumors or social media discussion not yet reflected in formal news coverage, or quarterly rebalancing by funds. Given that SLXN trades at a low price point ($0.32), it may also be subject to higher volatility and wider bid-ask spreads that can amplify intraday moves.

SONM

Sonim Technologies IncTechnology

$3.61−$0.77

-17.6%

NASDAQ · Mkt cap $3.2 M

Sonim Technologies fell 17.58% with no news in the past 48 hours, suggesting either a delayed negative announcement, technical selloff, or market-wide pressure in the rugged devices sector.

No headlines from the last 48 hours are available to explain the sharp 17.58% decline in SONM stock. This absence of news coverage is notable given the magnitude of the move. For a small-cap industrial equipment manufacturer like Sonim, which produces ruggedized smartphones and devices for enterprise customers, daily moves of this size are typically driven by earnings misses, guidance reductions, contract losses, or significant customer disruptions. The lack of visible catalysts could indicate that either the triggering event occurred before the 48-hour window, market participants are reacting to rumors or technical factors not yet reflected in mainstream news feeds, or an announcement is still pending. Without access to intraday trading data or company releases, identifying the precise cause remains speculative.

RAPP

Rapport Therapeutics, Inc. Common Stock

$34.22−$7.27

-17.5%

TVRD

Tvardi Therapeutics IncHealthcare

$1.31−$0.28

-17.4%

NASDAQ · Mkt cap $25 M

No news headlines were found in the last 48 hours, so the 17.35% drop cannot be attributed to a publicly reported event. The decline likely reflects broader biotech weakness, technical selling, or unreported developments.

Tvardi Therapeutics is a small-cap biotech company, and the complete absence of news headlines in the 48 hours surrounding a near-18% single-day loss makes it difficult to pinpoint a specific catalyst from public sources. Biotech stocks in this size category are often sensitive to several categories of events: clinical trial data releases (typically posted via SEC filings or press releases), FDA decisions or communications, partnership announcements, management changes, or broader sector sentiment shifts. It is also possible the move reflects technical factors, short covering reversals, or rumors circulating in equity research channels that may not yet have appeared in major news feeds. Without access to SEC filings, clinical trial registries, or delayed news feeds, the cause remains speculative.

SFIX

Stitch Fix Inc

$2.82−$0.48

-17.0%

JACS.RI

Jackson Acquisition Company II

$0.05−$0.01

-16.7%

RIBBR

Ribbon Acquisition Corp Rights

$0.25−$0.05

-16.5%

NASDAQ · Mkt cap $1.2 M

No news headlines were found in the last 48 hours to explain the 16.53% drop in RIBBR, making the direct cause unclear without additional context about broader market conditions or SPAC-specific dynamics.

Ribbon Acquisition Corp Rights (RIBBR) tracks the rights attached to a SPAC unit, which are typically among the most volatile and illiquid components of blank-check offerings. The absence of news in the search window means the decline was not driven by a specific identifiable catalyst like merger announcement, termination, or earnings. Rights offerings are sensitive to changes in the underlying SPAC's prospects, warrant pricing, redemption risk, and overall SPAC sentiment. The 16.53% single-day loss could reflect deteriorating interest in the parent SPAC structure, concerns about deal timing or sponsor reputation, or technical selling in a thinly traded security. Without headlines, we cannot distinguish between a market-wide SPAC pullback, company-specific news not yet captured in RSS feeds, or simple illiquidity amplifying normal price movement.

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.02−$0.00

-16.3%

NASDAQ · Mkt cap $1.1 M

No news headlines were found in the last 48 hours, so the 16.32% drop likely reflects either technical weakness in a micro-cap stock, delayed market reaction to an earlier announcement, or broader pressure on penny stocks.

The Alkaline Water Company is a micro-cap equity trading at $0.02 per share, a price point associated with high volatility and low liquidity. Without any news catalyst identified in the provided headlines from the last 48 hours, the decline cannot be directly attributed to company-specific events such as earnings misses, regulatory actions, or guidance cuts. For stocks at this valuation level, price moves of this magnitude are often driven by technical factors including forced liquidations, margin calls, short-covering reversals, or shifts in retail trading sentiment. It is also possible that news broke before the 48-hour window or that market participants are reacting to sector-wide pressures affecting beverage or alternative water companies. The absence of positive catalysts combined with the illiquid nature of the security makes it difficult to isolate a single driver.

LVO

LiveOne, Inc.Communication Services

$2.44−$0.46

-15.9%

NASDAQ · Mkt cap $52 M

LVO fell 15.86% despite positive news about Slacker Radio's five-year partnership with Groove Technology Solutions to serve the senior living market, suggesting the market may have reacted to other factors or viewed the partnership announcement as insufficient growth catalyst.

The most recent headline from September 22 announces a five-year partnership between LVO's Slacker Radio subsidiary and Groove Technology Solutions, expanding into a 3 million-bed U.S. senior living market with customized music experiences. This is typically positive news signaling revenue diversification and market expansion. However, the stock declined sharply the next trading day, which creates a disconnect. Possible explanations include: the market viewed the partnership deal terms as unfavorable or the revenue potential as overstated relative to investor expectations, or the decline was driven by unrelated factors such as broader sector weakness in audio streaming, company-specific operational concerns, or negative developments not captured in the provided headlines. Without access to trading volume, short interest activity, or other market context, the exact mechanism remains unclear.

KITT

Nauticus Robotics, Inc.

$0.52−$0.10

-15.8%

INNV

Innovus Pharmaceuticals, Inc.Healthcare

$9.00−$1.67

-15.6%

NASDAQ · Mkt cap $1.5 B

InnovAge announced a secondary offering of common stock by selling stockholders on September 22–23, 2026, which typically dilutes existing shareholders and triggered the 15.64% single-day sell-off.

The two news headlines both concern InnovAge's announcement of a secondary offering of common stock, with one dated September 22 describing the launch and the other dated September 23 announcing the pricing. A secondary offering by existing stockholders increases the share count in circulation without raising capital for the company itself, which mechanically dilutes earnings per share and ownership stakes for current holders. This is a textbook negative catalyst for equity holders. The timing of the announcement relative to the sharp one-day drop and the stock's rank as the 36th biggest loser strongly suggests the market immediately repriced the security downward upon learning of the dilution. No other material news or earnings surprises are evident in the provided headlines.

LTCH

Latch, Inc.Technology

$0.16−$0.03

-15.5%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours, so the 15.47% decline in LTCH cannot be directly attributed to a specific public announcement or earnings event. The drop likely reflects broad market sentiment, technical selling, or unannounced developments.

The absence of any headlines in the past two days makes it difficult to pinpoint a precise catalyst for LTCH's sharp decline today. The stock is trading at $0.16, suggesting it may already be in distressed territory, which typically makes such securities sensitive to broad market downturns, forced liquidations, or loss of investor confidence. For a micro-cap company like Latch in the proptech space, declines of this magnitude without visible news often stem from technical factors such as stop-loss cascades, short-selling activity, or delayed reporting of private developments that eventually surface. Without access to recent SEC filings, earnings dates, or material announcements, the most likely categories are market-wide headwinds affecting proptech, potential insider selling or dilution, or a negative rumor not yet reflected in major news feeds.

IAUX.WT

i-80 Gold Corp. WT

$1.10−$0.20

-15.4%

BMEA

Biomea Fusion, Inc.

$1.44−$0.26

-15.1%

AIRS

AirSculpt Technologies, Inc.Healthcare

$2.16−$0.38

-14.8%

NASDAQ · Mkt cap $203 M

No news headlines from the past 48 hours are available to explain AIRS' 14.84% decline, so the cause cannot be determined from the provided information.

AirSculpt Technologies dropped sharply on September 23rd with no corroborating headlines in the most recent news cycle. This absence of news does not rule out a specific catalyst. For a medical device or aesthetic procedure company like AIRS, typical triggers for sharp single-day losses include clinical trial setbacks, regulatory delays or denials, disappointing procedure volume or revenue guidance, competitive announcements, management changes, or analyst downgrades. The stock's position as the 40th biggest loser suggests broad selling pressure was present, though without headlines this could stem from sector rotation, technical selling into resistance, short-covering reversals, or a delayed market reaction to information not yet captured in the news feeds checked. The company's lower stock price point ($2.16) warrants caution about liquidity and potential distress signals, though this alone does not explain the specific timing.

VEEE

Twin Vee Powercats Co.Consumer Cyclical

$12.81−$2.18

-14.5%

NASDAQ · Mkt cap $6.2 M

Twin Vee Powercats dropped 14.54% with no news headlines in the last 48 hours, so the cause cannot be identified from available reporting; the move may reflect technical selling, sector weakness, or undisclosed company developments.

No recent news headlines were found in the Yahoo Finance RSS feed for the last 48 hours covering Twin Vee Powercats, which leaves the primary catalyst for this 14.54% single-day decline unestablished. For a small-cap marine powersports manufacturer like VEEE, typical drivers of sharp moves include quarterly earnings misses or withdrawals of guidance, supply chain or manufacturing disruptions, insider selling or dilutive equity raises, and sector-wide downturns in recreational boating demand. It is also possible the stock faced concentrated selling pressure unrelated to company-specific news—such as a redemption or index rebalancing—or that a significant announcement was made outside typical news distribution channels. Without headline confirmation, however, any specific explanation would be speculative inference rather than evidence-grounded analysis.

IMC

IMC Rare Earths LtdBasic Materials

$7.08−$1.20

-14.5%

NYSE · Mkt cap $1.1 B

IMC Rare Earths announced positive metallurgical testwork showing 73% in-situ rare earth recovery on September 22, yet the stock fell 14.49% the next day, suggesting the market either viewed the results as insufficient, priced in the news differently than expected, or reacted to other unmentioned…

The company released metallurgical testwork from the University of Brighton demonstrating encouraging rare earth recovery results at its Itarantim project, which on its surface appears constructive for a company focused on lower-cost recovery methods. However, a 14.49% drop immediately following this announcement indicates the market's reception was negative or neutral. Possible explanations include: the 73% recovery rate fell short of investor expectations or prior guidance, the cost savings were not as compelling as hoped, or the market interpreted the results as insufficient to de-risk the project timeline. Additionally, rare earth stocks are cyclical and sensitive to commodity price movements, geopolitical shifts, and production bottleneck concerns that are not addressed in the provided headlines. Without context on prior analyst expectations, management guidance, or competing news, the disconnect between positive technical data and sharply negative price action remains unexplained by the headline alone.

CTEV

MultiPlan CorporationHealthcare

$25.13−$4.25

-14.5%

NYSE · Mkt cap $662 M

CTEV fell 14.47% on September 23rd despite a positive contract award announcement from the prior day, suggesting the market may have reacted negatively to details in the Claritev-GDIT-CDC deal or broader sector/company headwinds unrelated to the headline news.

The only recent news provided is a September 22nd announcement that Claritev (CTEV) was selected by GDIT to support the CDC's World Trade Center Health Program. This appears to be a positive development—a new government contract win for a healthcare technology and data company. However, the stock dropped sharply the following day, which is counterintuitive if the market embraced the news. Possible explanations include: (1) the deal size or terms may be less lucrative than initial perception, (2) investors may have learned negative details about the contract duration, margins, or competitive dynamics after digging deeper, or (3) the decline reflects broader market sell-off in healthcare IT or data services stocks unrelated to this specific contract. Without additional news from September 23rd or detailed financial guidance, it is difficult to pinpoint the exact cause of the 14.47% drop.

KPLT

Katapult Holdings, Inc.Technology

$7.12−$1.19

-14.3%

NASDAQ · Mkt cap $29 M

No news headlines were found in the last 48 hours to explain Katapult's 14.32% decline, so the cause remains unclear from available information.

Katapult Holdings dropped sharply on September 23rd without any identifiable news catalyst in the Yahoo Finance RSS feed over the preceding two days. This absence of headline news does not rule out a cause—the move could reflect delayed market reaction to an earlier announcement, broad sector selloff pressure, technical trading, analyst downgrades not yet syndicated widely, insider trading activity, or changes in company guidance or operational metrics announced through other channels not captured in this feed. For a consumer finance and point-of-sale lending platform like Katapult, typical catalysts include changes in credit quality metrics, funding costs, regulatory developments affecting fintech lending, or shifts in consumer spending. Without substantive news or knowledge of Katapult's specific corporate structure or recent investor communications, the driver of this move cannot be pinpointed from the data at hand.

AMOD

Insight Acquisition Corp.Technology

$1.65−$0.27

-14.0%

NASDAQ · Mkt cap $22 M

No news headlines were published in the last 48 hours, so the cause of AMOD's 14% drop cannot be attributed to a specific announced event; the decline likely stems from technical selling, broader market weakness, or untracked developments.

AMOD (Insight Acquisition Corp.) is a blank-check company or SPAC, a security type that typically experiences volatility linked to deal announcement timing, investor confidence in management, redemption risk, or lack of liquidity. The absence of any news in the prior 48 hours means the drop was not triggered by an identifiable corporate action like a merger announcement, deal termination, or guidance change. For SPACs, common drivers of sharp declines include loss of investor confidence in deal prospects, redemption pressure as a merger deadline approaches, insider selling signals, or broader sentiment shifts toward blank-check vehicles. Without concrete headline evidence, this move falls into the category of either technical momentum selling or an unannounced development (delayed filing, internal complication, or market-wide deleveraging affecting lower-liquidity securities).

CBIO

Catalyst Biosciences IncHealthcare

$14.17−$2.30

-14.0%

NASDAQ · Mkt cap $758 M

No news headlines were found in the last 48 hours, so the 13.96% decline likely reflects either a delayed market reaction to an earlier announcement, sector-wide biotech weakness, or an undisclosed company-specific event.

Catalyst Biosciences is a clinical-stage biopharmaceutical company, and large single-day drops in this sector typically correlate with clinical trial setbacks, regulatory decisions, financing announcements, or shifts in development strategy. The absence of recent headlines in the search results does not mean no news occurred; it may indicate the market is reacting to news from before the 48-hour window, or that the move reflects technical selling, sector rotation, or proprietary news flow not yet captured in public RSS feeds. Biotech stocks are particularly sensitive to clinical readouts, FDA feedback letters, and capital raise announcements. Without a specific headline tying to this drop, the cause remains unclear but contextually likely to fall into one of those categories.

TRNR

Interactive Strength Inc. - Common StockConsumer Cyclical

$2.65−$0.41

-13.9%

NASDAQ · Mkt cap $4.2 M

Interactive Strength published a shareholder letter highlighting record Q2 revenue, 48% gross margins, and robust M&A pipeline on the same day the stock fell 13.90%, suggesting either a delayed market reaction, unmet growth expectations relative to forward guidance, or concern about execution ris…

The headline announces objectively positive Q2 results: record revenue, significant gross margin expansion from 31% to 48%, and a strong M&A pipeline. However, a 13.90% decline on the day these results were published is unusual and counterintuitive. Three explanations are plausible: first, the market may have expected even stronger results or forward guidance that was not delivered; second, investors may view the stated M&A pipeline as overly optimistic or dilutive; third, the timing of publication relative to market close or broader sector weakness could have obscured the positive news. Without access to the full letter's guidance statements, margin sustainability commentary, or the company's historical execution credibility, it is difficult to definitively explain the disconnect between headline quality and stock performance.

GPUS-D

Hyperscale Data, Inc.

$16.66−$2.67

-13.8%

GPUS.PR.D

Hyperscale Data, Inc.

$16.66−$2.67

-13.8%

LXEO

Lexeo Therapeutics, Inc.

$3.52−$0.55

-13.5%